Facebook
X
LinkedIn
Forward13th International Clinical Cancer Genomics Conference: Accelerating Technology Enabled Precision Oncology
Chicago, IL US
April 23, 2026 to April 25, 2026
Advancements in biomarker and genomic technologies continue to transform cancer care, enabling personalized risk assessment, targeted screening, and precision treatments. As we enter a new era of precision medicine, comprehensive understanding of cancer genomics and the immune microenvironment allows clinicians to identify individuals at the highest risk for lethal, yet treatable, malignancies—thus optimizing surveillance, prevention, and patient outcomes. Landmark achievements, such as the identification of BRCA1 mutation carriers (enabling cancer prevention strategies and PARP inhibitor therapy) and the management of Lynch Syndrome (leading to curative immunotherapeutic approaches for rectal cancer), illustrate the profound impact of genomics on the continuum of care.
We are convening a 3-day in-person conference with 20 world-renowned faculty experts in cancer genomics and over 500 participants with the goal of establishing a Learning Group Network of up to 1000 people at the 13th International Clinical Cancer Genomics Conference—Accelerating Technology Enabled Precision Oncology, where stakeholders will share state-of-the-art science, latest technologies—including Artificial Intelligence—real-world case studies, curated pedigrees, and actionable case summaries. This forum is designed to equip healthcare professionals with practical tools and evidence-based guidelines for managing high-risk patients and their families, with a strong emphasis on technologies that broaden access to biomarker-informed, patient centric precision oncology across the continuum of care from prevention to survivorship.
Target Audience
This activity has been designed for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, pharmacists, and other healthcare professionals currently involved in providing cancer genetics risk assessment services or initiating such services in their health care system. Special efforts will be made to meet the needs of clinicians practicing in non-academic centers and geographically and/or socioeconomically underserved communities.
Learning Objectives
After participating in the activity, participants should be better able to:
- Collaborate with patient advocates to bring patient voices to round table discussions and platform presentations;
- Review advances in genetics, genomics, and next generation Omics technologies transforming precision oncology;
- Evaluate controversies in risk prediction and genomic testing for management decisions, including integration of liquid biopsies into risk adapted treatment;
- Discuss emerging concepts in digital pathology, and integration of Artificial Intelligence in developing Multi-Omics-based biomarkers;
- Develop innovative mentoring platforms for trainees and introduce early Career Researchers to International Genomics focused Consortia such as ENIGMA, CIMBA, Africa Oncogenetics Network, Asia Oncogenetics Network and America Oncogenetics Network;
- Debate ethical implications and opportunities presented by AI tools in health care.
You may also be interested in
| THURSDAY, APRIL 23, 2026 | ||
| Time | Session | |
| Pre-conference: Hereditary Hematologic Cancers Primer and Case-Based Workshop Location: Renaissance Ballroom | ||
| 8:00am–8:10am | Welcome, Introductions, Overview — Kathleen Blazer, Director & Jane Churpek, MD, MS, Program Chair | |
| 8:10am–8:25am | Basics of Hematology Relevant to Germline Genetic Testing — Jane Churpek, MD, MS | |
| 8:25am–8:40am | Indications and Guidelines for Germline Testing in Patients with Hematologic Malignancies/Disorders — Christopher Reilly, MD | |
| 8:40am–8:55am | New Horizons in Genetic Test and Sample Type Selection for Hereditary Hematologic Malignancy Syndromes — Lauren Banaszak, MD | |
| 8:55am–9:10am | Updates on Variant Curation and Interpretation for Hematologic Malignancy Predisposition Disorders — Lucy Godley, MD | |
| 9:10am–9:25am | Implementing a Hereditary Hematology Program — Raymond Kim, MD and Brittany Stewart, MS, CGC | |
| 9:25am–9:45am | Q&A / Participant and Panel Discussion | |
| 9:45am–9:50am | Break | |
| 9:50am–10:45am | Putting It All Together: Team-Based Learning (TBL) Part 1: Breakout Sessions Faculty Panel: Jane Churpek, MD, MS; Christopher Reilly, MD; Lauren Banaszak, MD; Lucy Godley, MD; Raymond Kim, MD; Brittany Stewart, MS, CGC Moderators: TBA | |
| 10:45am–12:00pm | Putting It All Together: Team-Based Learning (TBL) Part 2: Case Review and Discussion Faculty Panel: Jane Churpek, MD, MS; Christopher Reilly, MD; Lauren Banaszak, MD; Lucy Godley, MD; Raymond Kim, MD; Brittany Stewart, MS, CGC Moderators: Emma Adams, MS, CGC; Alex Capasso, MS, CGC; Lauren Gima, MS; Bita Nehoray, MS, CGC; Elise Sobotka, MS, MPH, CGC; Kaila Wilson, MS, CGC; Elyssa Zukin, MS, CGC; Suzie Shehayeb, MS, CGC; Sandra Dreike, MS, CGC; Ilana Solomon, ScM, CGC; Christina Rybak, MS, CGC; Feighanne Hathaway, MS, CGC | |
| 12:00pm–12:05pm | Pre-Conference Summary / Closing Remarks | |
| 12:05pm–2:00pm | Break | |
| 12:30pm–1:30pm | Non-CME Product Theater: TBD (Location: Armstrong) | |
| 1:30pm–2:20pm | Opening Remarks & Historical Perspective on the Evolution of Cancer Genetics — Cancer Center Director: Kunle Odunsi, MD, PhD | |
| Session 1: Genetic Testing is Getting More Complicated! Specimens and Technologies Moderators: Sulin Wu, MD, PhD & Feighanne Hathaway, MS, CGC Location: Grand Ballroom | ||
| 2:20pm–2:50pm | Leveraging Artificial Intelligence for Automated Interpretation of Cancer Variants — Jeremy Segal, MD | |
| 2:50pm–3:20pm | Keynote Address I: Solving Difficult Variants with New Specimens and Technologies: Long-read Sequencing, Paired Tumor, RNA Testing — Tom Walsh, PhD | |
| 3:20pm–3:50pm | Mutation Signatures as Clues to the Underlying Gene — Kara Maxwell, MS | |
| 3:50pm–4:20pm | Complexities of Risk Estimation, Test Interpretation and Cancer Risk Management — Tuya Pal, MD | |
| 4:20pm–5:00pm | Great Debate: Should VUS be clinically reported? — Heather Hampel, MS and Colin Pritchard, MD | |
| 5:00pm–5:15pm | Question & Answer Panel Discussion | |
| 5:15pm–7:00pm | Welcome Reception & Poster Session (Location: Renaissance Ballroom) | |
| 7:30pm | Faculty Dinner | |
| FRIDAY, APRIL 24, 2026 | ||
| Time | Session | |
| 7:00am–7:50am | Non-CME Breakfast Product Theater: TBD (Location: Armstrong) | |
| Session 2: 30+ years after BRCA1 and BRCA2 Discoveries – Lessons Learned about Menopause and Survivorship Moderators: Lorraine Canham, MD & Rodrigo Guindalini, MD Location: Grand Ballroom | ||
| 8:00am–8:10am | Welcome and Announcements | |
| 8:10am–8:35am | Taking Care of Women Across the Lifespan – Birth Control and Fertility Issues — Nicole Edison, MD | |
| 8:35am–8:55am | Update on Risk Reducing Surgeries — Nora Jaskowiak, MD | |
| 8:55am–9:15am | Hormonal Therapy & Transgender Care — Iris Romero, MD | |
| 9:15am–9:45am | Keynote Address II: Hormone Replacement Therapy in HBOC Patients and Long-Term Outcomes — Joane Kotsopoulos, PhD | |
| 9:45am–10:00am | Question & Answer Panel Discussion Panelists: Nicole Edison, MD; Nora Jaskowiak, MD; Iris Romero, MD; Joane Kotsopoulos, PhD | |
| 10:00am–10:30am | Voices of Patient Advocates Moderators: Lisa Madlensky, PhD, CGC and Olufunmilayo Olopade, MD Panelists: Kathy Baker, Lateesha Barnes, Ricki Fairley, & Joelle Kaufman | |
| 10:30am–11:00am | Break | |
| Session 3: Transforming Hematology/Oncology Care through Genetics Moderators: Daniel Arber, MD & Olufunmilayo Olopade, MD Location: Grand Ballroom | ||
| 11:00am–11:45am | Dr. Harvey Golomb Distinguished Lectureship in Cancer Genetics — Ashok Venkitaraman, MBBS, PhD | |
| 11:45am–12:00pm | Update on Cancer Genetics Education Across the Globe — Charles Balch, MD | |
| 12:00pm–12:15pm | Young Onset Lung Cancer — Marina Garassino, MD | |
| 12:15pm–12:30pm | BRCA and Bone Marrow Disorders — Jane Churpek, MD, MS | |
| 12:30pm–2:00pm | Lunch | |
| 1:00pm–1:50pm | Non-CME Product Theater: TBD (Location: Armstrong) | |
| Session 4: Case Presentations with Interprofessional Panel Discussions Moderators: Jane Churpek, MD, MS & Bita Nehoray, MS, CGC Location: Grand Ballroom | ||
| 2:00pm–3:30pm | Case Presentations with Interprofessional Panel Discussions Focused on Incorporating Germline and Somatic Genetic Data into Patient Risk Management and Precision Cancer Treatment Panel: Colin Pritchard, MD, PhD; Kara Maxwell, MD, PhD; Heather Hampel, MS, CGC; Pamela Ganschow, MD; Elias Obeid, MD, MPH; Michael Hall, MD Moderators: Bita Nehoray, MS, CGC; Lauren Gima, MS, CGC; Suzie Shehayeb, MS, CGC; Sandra Dreike, MS, CGC; Ilana Solomon, MS, CGC; Christina Rybak, MS, CGC; Elyssa Zuken, MS, CGC; Elise Sobotka, MS, CGC | |
| Session 5: 30+ years after BRCA1 and BRCA2 Discoveries – Lessons learned from Management of Multiple Cancers Moderators: Emma Sass and Elias Obeid, MD, MPH Location: Grand Ballroom | ||
| 3:30pm–4:00pm | Keynote Address III: Breast Cancer Information Core — 30+ years of Curation to Advance HBOC Cure — Lawrence Brody, PhD | |
| 4:00pm–4:25pm | Precision Oncology to Impact Men’s Health — Ari Rosenberg, MD | |
| 4:25pm–4:45pm | Parp Inhibitors in Hematology — Michael Drazer, MD, PhD | |
| 4:45pm–5:00pm | Question & Answer Panel Discussion Panelists: Lawrence Brody, PhD; Ari Rosenberg, MD; Michael Drazer, MD, PhD | |
| 5:00pm–5:45pm | Breakout Sessions – Late Breaking Topics Room Topic: Innovations in High Risk Screening — Kirti Kulkarni, MD & Milica Medved, PhD, DAPMB Moderators: Greg Karczmar, PhD and Olufunmilayo Olopade, MD Room Topic: High Risk Breast & Prostate Cancer — Elias Obeid, MD, MPH & Joanne Jeter, MD Moderator: Iris Romero, MD and Sulin Wu, MD, PhD Room Topic: Breast Cancer Prevention Studies: Challenges & Opportunities — Adetunji Toriola, MD, PhD & Jeffrey Weitzel, MD Moderator: Rodrigo Guindalini, MD and Wenji Guo, MD, PhD | |
| 5:45pm | Adjourn | |
| 7:00pm | Gala | |
| SATURDAY, APRIL 25, 2026 | ||
| Time | Session | |
| 7:00am–7:50am | Non-CME Breakfast Product Theater: TBD (Location: Armstrong) | |
| Session 6: AI Integration into Oncology Care Moderator: Anna Woodard, PhD and Subomi Omoleye, MD Location: Grand Ballroom | ||
| 8:10am–8:35am | Harnessing AI for Risk Stratification and Precision Treatment in Breast Cancer — Frederick Howard, MD | |
| 8:35am–9:00am | Population Risk Stratification using SNPs and Mammographic AI — Jeffrey Tice, PhD | |
| 9:00am–9:25am | AI in Mammography Screening: Are We There Yet? — Randy Miles, MD | |
| 9:25am–9:55am | Keynote Address V: Multi-Omics Approach to Breast Cancer Risk Prediction — Adam Yala, PhD | |
| 9:55am–10:15am | Question & Answer Panel Discussion Panelists: Frederick Howard, MD; Jeffrey Tice, PhD; Randy Miles, MD; Adam Yala, PhD | |
| 10:15am–10:45am | Break | |
| Session 7: Accelerating Progress in Early Detection & Cancer Interception Moderators: Jan-Marie McEvilly, RN, MS, OCN & Pamela Ganschow, MD Location: Grand Ballroom | ||
| 10:45am–11:05am | Cancer Risks in Older Women — Kelly Metcalfe, RN, PhD | |
| 11:05am–11:30am | Keynote Address VI: Communicating Health Risks to Women: Lessons from the United Kingdom — Itunu Johnson-Sogbetun, MBBS | |
| 11:30am–11:50am | Obesity, Pharmacotherapy, and the Disease-modifying Effects of GLP-1–based Therapies — Silvana Pannain, MD | |
| 11:50am–12:30pm | Question & Answer Panel Discussion | |
| 12:30pm–2:00pm | Lunch | |
| 1:00pm–2:50pm | Non-CME Product Theater: TBD (Location: Armstrong) | |
| Session 8: Will Immuno Oncology Accelerate Cures In High Risk Populations: Technology, Testing, Treatment Moderators: Christine Drogan, MS, CGC & Lorraine Canham, MD Location: Grand Ballroom | ||
| 2:00pm–2:20pm | Keynote Address VII: Vaccines for Women's Cancer: Lessons Learned — Nita Lee, MD, MPH | |
| 2:20pm–2:40pm | Immuno Oncology Update for Lynch Syndrome Cancers: Successes and Failures — Michael Hall, MD | |
| 2:40pm–3:00pm | Rapid Fire Sessions Moderator: Lisa Madlensky, PhD, CGC and Michael Drazer, MD, PhD (podium presentations from selected abstract submissions) | |
| 3:00pm–3:15pm | Break | |
| Session 9: Expanding Infrastructure to Implement Biomarker Informed Clinical Trials and Precision Oncology at Scale Moderators: Jeffrey Weitzel, MD and Michael Mullane, MD Location: Grand Ballroom | ||
| 3:15pm–3:35pm | Implementation Science to Expand Navigational Services for Precision Oncology — Ted Skolarus, MD | |
| 3:35pm–3:55pm | VHL Center of Excellence: Implications of germline findings in Renal Cell Carcinoma — Jonathan Trujillo, MD, PhD | |
| 3:55pm–4:15pm | Developing a Center of Excellence for Women's Cancers in Ontario Canada for Impact across the Globe — Steven Narod, MD | |
| 4:15pm–4:45pm | Wrap Up: The Future of Cancer Interception Studies — Judy Garber, MD, MPH and Olufunmilayo Olopade, MD | |
The agenda is subject to change.
InterContinental Chicago Magnificent Mile by IHG
505 North Michigan Avenue
Chicago, IL
60611
United States
WANT TO KNOW MORE?
Learn more about the program by visiting the conference website! For questions, contact Kristen at Meeting Achievements via e-mail.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office via e-mail at [email protected].
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
CONFERENCE LEADERSHIP
Olufunmilayo Falusi Olopade, MBBS, FACP
Walter L. Palmer Distinguished Service Professor
Director, Center for Clinical Cancer Genetics
Departments of Medicine and Human Genetics
University of Chicago
Walter L. Palmer Distinguished Service Professor
Director, Center for Clinical Cancer Genetics
Departments of Medicine and Human Genetics
University of Chicago
Kathleen Blazer, EdD, MS, LCGC
Clinical Assistant Professor
Associate Director, Cancer Genomics Education Program
Co-Director, Intensive Course in Cancer Risk Assessment
Co-Investigator, Cancer Genomics Career Development Program
City of Hope National Medical Center
Clinical Assistant Professor
Associate Director, Cancer Genomics Education Program
Co-Director, Intensive Course in Cancer Risk Assessment
Co-Investigator, Cancer Genomics Career Development Program
City of Hope National Medical Center
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Genetic Counselor Credit
The National Society of Genetic Counselors (NSGC) has authorized University of Chicago Pritzker School of Medicine to offer up to 2.100 CEUs or 21Category 1 contact hours for the activity 13th International Clinical Cancer Genomics Conference. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.
Nursing Credit
University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 21 contact hours.
Participants who successfully complete the entire activity and complete an evaluation form will earn 21 contact hours.
American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Health Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other Health Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please note: The credit claiming process will close 30 days after the activity ends. Requests to claim credit after 30 days may incur additional fees.
For more information on opportunities for exhibits and sponsorships, please contact:
Annie Smith, CMP
Phone: 219.465.1115 Ext. 114
Email: [email protected]
Registration: Click the button below for complete registration information and to register.
REGISTRATION
REGISTRATION
Claiming Credit: After the conference, create or log into your UChicago CME account and enter the access code to unlock the credit claiming process.
Please note: The credit claiming process will close 30 days after the activity ends. Requests to claim credit after 30 days may incur additional fees.
Please login or create an account to proceed.